New drug itacitinib tested for Hard-to-Treat myelofibrosis
NCT ID NCT04629508
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 study tested the drug itacitinib in 4 people with myelofibrosis (a bone marrow disorder) who had already tried other treatments like ruxolitinib or fedratinib. The main goals were to check safety and find the right dose, and to see if it could shrink an enlarged spleen. The study is now complete, but with only 4 participants, it provides very early information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
itacitinib
What this could lead to
If it works, itacitinib could offer a new treatment option for myelofibrosis patients who no longer respond to or cannot tolerate current therapies.
What could go wrong
This is a very small, early-phase study (only 4 participants) focused on safety and dosing. It is not designed to prove effectiveness, and results may not apply to larger populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ DELTA
Roeselare, 08800, Belgium
-
Aou San Giovanni Di Dio E Ruggi
Salerno, 84131, Italy
-
Baptist Cancer Center
Memphis, Tennessee, 38120, United States
-
Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, 05530, Belgium
-
Cliniques Universitaires Ucl Saint-Luc
Brussels, 01000, Belgium
-
Hospital Universitari I Politecnic La Fe
Valencia, 46000, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Interne 1 - Hematologie Mit Stammzelltransplantation, Hemostaseologie Und Medizinische Onkologie Ord
Linz, 70376, Austria
-
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Milan, 20132, Italy
-
Jessa Ziekenhuis
Hasselt, 03500, Belgium
-
Midamerica Cancer Care
Kansas City, Missouri, 64114, United States
-
New Jersey Hematology Oncology Associates Llc
Brick, New Jersey, 08724-3009, United States
-
Pratia Hematologia Katowice
Katowice, 40-519, Poland
-
Rcca Md, Llc
Bethesda, Maryland, 20817, United States
-
Renovatio Clinical Consultants Llc
Spring, Texas, 77380, United States
-
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas, 75246-2092, United States
-
Treviso Hospital
Treviso, 31100, Italy
-
Tulane University
New Orleans, Louisiana, 70112, United States
-
Universitaetsmedizin Greifswald
Greifswald, 17475, Germany
-
Universitatsklinikum Halle (Saale)
Halle, 06120, Germany
-
Vanderbilt University
Nashville, Tennessee, 37235, United States